Autor: |
Ulla Stumpf, Karel Kostev, Iannis Kyvernitakis, Wolfgang Böcker, Peyman Hadji |
Jazyk: |
angličtina |
Rok vydání: |
2019 |
Předmět: |
|
Zdroj: |
Journal of Bone Oncology, Vol 18, Iss , Pp - (2019) |
Druh dokumentu: |
article |
ISSN: |
2212-1374 |
DOI: |
10.1016/j.jbo.2019.100254 |
Popis: |
In recent years, cancer treatment-induced bone loss (CTIBL) and increased risk of fracture has become an emerging problem as breast cancer (BC) survival has increased due to early diagnosis and improved treatments. In premenopausal women with BC, chemotherapy and tamoxifen are the treatments of choice in hormone receptor-negative and hormone receptor-positive BC respectively. Their effect on fracture risk has only been investigated in a few small-scale studies.Therefore, we investigated the fracture risk in a cohort study based on data from the Disease Analyzer database (IQVIA) and included 1761 individuals with BC and 1761 healthy women for comparison. After applying similar inclusion criteria, patients with BC were matched 1:1 to those without BC with regard to age, index year, and physician. Within 10 years of the index date, 6.4% of healthy women and 14.2% with BC sustained a fracture (log-rank p-value |
Databáze: |
Directory of Open Access Journals |
Externí odkaz: |
|